Amphastar Pharmaceuticals
Last updated Jun 18, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
72%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Neurology
- Opioid Overdose
Highest priority development: FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
Regulatory precedent
Why this matters: sets a approval precedent in the same sub-indication (pain) as Amphastar Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 72%
Active Signals
1
Investigate Priority
0
Opportunity Score
17
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 18, 2026Score 17FDA Approves Supplemental Application for REXTOVY by Amphastar Pharmaceuticals
Neurology · Opioid Overdose
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney InjuryHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Investigational New Drug (IND) ApplicationModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinomaModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancerModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Amphastar Pharmaceuticals right now?
- Which regulatory precedents should Amphastar Pharmaceuticals monitor in Neurology and Opioid Overdose?
- How does Regulatory Developments Reshaping Competitive Landscape in Neurology Markets compare to the nearest competitive programs?
- What signals require immediate investigation for Amphastar Pharmaceuticals?
- Summarize the strategic implications of recent developments for Amphastar Pharmaceuticals.
- Where is the greatest uncertainty in Amphastar Pharmaceuticals's competitive positioning?